CCR2 and focal segmental glomerulosclerosis: We hypothesized that simultaneous inhibition of CCR2 and angiotensin 2 receptor type 1 would inhibit CCR2-mediated inflammatory pathways on podocytes and monocytes and reduce proteinuria in patients with FSGS.